LOW COST HIV DRUG RESISTANCE MONITORING

低成本 HIV 耐药性监测

• 批准号: 2790154
• 负责人: JACK R. U'REN
• 金额: $ 37.51万
• 依托单位: SAIGENE CORPORATION
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-30 至 2001-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2790154
• 关键词: AIDS /HIV test; DNA primers; HIV infections; diagnosis design /evaluation; drug resistance; human immunodeficiency virus; nucleic acid sequence; polymerase chain reaction; serology /serodiagnosis; technology /technique development; virulence; virus load

DESCRIPTION: (Adapted from Applicant's Abstract) Drug resistance is the single greatest reason for lack of HIV control. Quantitative measurements of viral load and drug resistance can provide the information necessary to rationally modify drug therapy. Increasing viral load can be caused by changes in the immunologic status of the patient or the virulence of the virus or by lack of patient compliance with the difficult drug scheduling. Treating patients who may have been infected with a drug resistant virus with combination drug therapy may be detrimental to the patient. Knowing the precise nature of a drug resistant mutation can also be used to predict cross-resistance or reduced resistance to other drugs. This work will develop RT-PCR conditions, primers, capture sequences, and internal standards that make quantitative detection of wild-type and drug-resistant HIV a simple and rapid process, even while accommodating the known sequence polymorphism found in the virus. In this Phase II study, the developed detection assay for the common reverse transcriptase inhibitors (AZT, ddI, ddC, and 3TC) will be expanded to include the protease inhibitors (indinavir, ritonavir, saquinavir, and nelfinavir) and evaluated using clinical samples. The results from this assay will be compared with the more costly DNA sequencing methods and a competing oligonucleotide ligation assay. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（改编自申请人的摘要）耐药性是单个 缺乏艾滋病毒控制的最大原因。病毒的定量测量 负载和耐药性可以提供理性的必要信息 修改药物疗法。增加病毒负荷可能是由变化引起的 患者的免疫学状态或病毒的毒力或缺乏 患者遵守困难的药物调度。治疗患者 可能已经被联合药物感染了耐药病毒 治疗可能对患者有害。知道药物的确切性质 耐药突变也可用于预测越野抗性或降低 对其他药物的抵抗力。这项工作将发展RT-PCR条件，引物， 捕获序列和内部标准，以定量检测 野生型和耐药的HIV也是一个简单而快速的过程 适应病毒中发现的已知序列多态性。在这个阶段 II研究，开发的常见逆转录酶的检测测定 抑制剂（AZT，DDI，DDC和3TC）将扩展到包括蛋白酶 抑制剂（Indinavir，Ritonavir，Saquinavir和Nelfinavir），并进行了评估 使用临床样品。该测定的结果将与 更昂贵的DNA测序方法和竞争性的寡核苷酸连接 测定。 拟议的商业应用程序：不可用